Stanley Riddell’s group have developed an ‘AND’ gated ROR-1 specific CAR T cell which improved the safety of targeting this TAA by requiring the coexpression of another protein; EpCAM, or, for more tumor specificity B7-H3, preventing direction of cytotoxicity towards ROR-1 expressing stromal cells.56 Interestingly, protection of ROR-1 stromal cells was only found to occur when there was a spatial segregation between malignant and healthy cells. Here, ROR1 is linked to neoplasm.